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Background: The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if
approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization. Safety,
immunogenicity and efficacy of the RTS,S/AS02D vaccine candidate when integrated into a standard EPI schedule
for infants have been reported over a nine-month surveillance period. This paper describes results following
20 months of follow up.
Methods: This Phase IIb, single-centre, randomized controlled trial enrolled 340 infants in Tanzania to receive three
doses of RTS,S/AS02D or hepatitis B vaccine at 8, 12, and 16 weeks of age. All infants also received DTPw/Hib
(diphtheria and tetanus toxoids, whole-cell pertussis vaccine, conjugated Haemophilus influenzae type b vaccine) at
the same timepoints. The study was double-blinded to month 9 and single-blinded from months 9 to 20.
Results: From month 0 to 20, at least one SAE was reported in 57/170 infants who received RTS,S/AS02D (33.5%;
95% confidence interval [CI]: 26.5, 41.2) and 62/170 infants who received hepatitis B vaccine (36.5%; 95% CI: 29.2,
44.2). The SAE profile was similar in both vaccine groups; none were considered to be related to vaccination. At
month 20, 18 months after completion of vaccination, 71.8% of recipients of RTS,S/AS02D and 3.8% of recipients of
hepatitis B vaccine had seropositive titres for anti-CS antibodies; seroprotective levels of anti-HBs antibodies
remained in 100% of recipients of RTS,S/AS02D and 97.7% recipients of hepatitis B vaccine. Anti-HBs antibody GMTs
were higher in the RTS,S/AS02D group at all post-vaccination time points compared to control. According to
protocol population, vaccine efficacy against multiple episodes of malaria disease was 50.7% (95% CI: -6.5 to 77.1,
p = 0.072) and 26.7% (95% CI: -33.1 to 59.6, p = 0.307) over 12 and 18 months post vaccination, respectively. In the
Intention to Treat population, over the 20-month follow up, vaccine efficacy against multiple episodes of malaria
disease was 14.4% (95% CI: -41.9 to 48.4, p = 0.545).
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Conclusions: The acceptable safety profile and good tolerability of RTS,S/AS02D in combination with EPI vaccines
previously reported from month 0 to 9 was confirmed over a 20 month surveillance period in this infant
population. Antibodies against both CS and HBsAg in the RTS,S/AS02D group remained significantly higher
compared to control for the study duration. Over 18 months follow up, RTS,S/AS02D prevented approximately a
quarter of malaria cases in the study population.
Clinical trials: Gov identifier: NCT00289185
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Globally, in 2010, an estimated 216 million people had
malaria, 81% of which were from sub-Saharan Africa [1].
In 2010 in Africa, malaria resulted in approximately
596,000 deaths, 91% of which were in children under
five years of age. Among the many approaches being
pursued to control the disease, the development of safe
and efficacious vaccines has been given high priority by
national and international health authorities [2]. Used in
conjunction with other control measures, a vaccine
offers the possibility of accelerating and increasing the
effectiveness of integrated malaria control.
The RTS,S/AS candidate malaria vaccine is being
developed for the routine immunization of infants and
children living in malaria-endemic areas as part of the
Expanded Programme of Immunization (EPI). The can-
didate vaccine has been evaluated with two different
proprietary adjuvant systems, AS02 and AS01, both indi-
cating an acceptable safety profile in children [3-10] and
infants [11-13] in clinical trials.
A Phase IIb trial was conducted between July 2006 and
February 2008 in Tanzania [12]. Infants aged 6 to 10 weeks
at first vaccination received either RTS,S/AS02D or a
hepatitis vaccine (Engerix-B™, GlaxoSmithKline [GSK]) as
control. The RTS,S/AS02D candidate malaria vaccine con-
sists of sequences of the circumsporozoite (CS) protein
and hepatitis B surface antigen (HBsAg) with the adjuvant
AS02D (proprietary oil-in-water emulsion formulated with
MPL and QS21 immunostimulants). Both study vaccines
were administered together with a vaccine containing
diphtheria and tetanus toxoids, whole-cell pertussis vac-
cine, and conjugated Haemophilus influenzae type b vac-
cine (DTPw/Hib) (TETRActHib™, Aventis Pasteur).
As reported previously, over a nine-month surveillance
period, serious adverse events (SAEs) were reported in a
similar proportion of subjects receiving the RTS,S/
AS02D candidate vaccine (18.2%; 95% confidence inter-
val [CI]: 12.7, 24.9) and hepatitis B vaccine (24.7%; 95%
CI: 18.4, 31.9). Non-inferiority of the RTS,S/AS02D can-
didate vaccine in terms of antibody responses to EPI
antigens was demonstrated. RTS,S/AS02D was shown to
be highly immunogenic for anti-CS and -HBs antibodies.
Using active detection of infection, efficacy of theRTS,S/AS02D candidate vaccine against first Plasmo-
dium falciparum infection was 65.2% (95% CI: 20.7,
84.7; p = 0.01) over a 6 month period [12].
This paper presents the 20 month follow up compara-
tive data on the safety, immunogenicity and, as an ex-
ploratory endpoint, efficacy against malaria disease of
RTS,S/AS02D in combination with EPI vaccines in the
same population of infants aged six to 10 weeks at first
vaccination.
Methods
Study design
Details of study design, study vaccines and subject enrol-
ment have been published elsewhere [12]. In brief, the
study was a single centre, Phase IIb, randomized, con-
trolled study conducted by the Bagamoyo Research and
Training Centre, a branch of the Ifakara Health Institute
(IHI; previously Ifakara Health Research and Develop-
ment Centre-IHRDC) in Bagamoyo, Tanzania. The study
was double-blind from months 0 to 9 and single-blind
from months 9 to 20.
The protocol was approved by the Ifakara Health
Institute, the National Institute of Medical Research in
Tanzania, Western Institutional Review Board in the United
States, the Institutional Review Board of the London School
of Hygiene and Tropical Medicine, and the Swiss Tropical
and Public Health Institute (Swiss TPH, previously Swiss
Tropical Institute; STI) through the local government ethics
committee in Basel, Switzerland. The trial was undertaken
in accordance with the provisions of the International
Conference on Harmonization and Good Clinical Practice
guidelines and was monitored by the sponsor, GSK Biologi-
cals, which provided both the RTS,S/AS02D candidate vac-
cine and the hepatitis B vaccine.
The design, conduct, and results of the trial were over-
seen by a formally constituted Independent Data Monitor-
ing Committee (IDMC), operating under a charter. The
IDMC included experts in malaria, paediatricians, and sta-
tisticians who were appointed to oversee the ethical and
safety aspects of the study conduct. The role of the IDMC
included review of the implementation and progress of
the study. It provided initial, regular, and closing advice on
safety-related issues to the sponsor. The trial aims and
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and written informed consent in Swahili was obtained
from each child’s parent(s) or guardian(s) before study
procedures were initiated. Non-literate parents or guar-
dians indicated consent using a thumbprint, and a signa-
ture was obtained from a literate witness.
Malaria transmission in Bagamoyo area is perennial
and almost entirely due to P. falciparum. Distribution
of insecticide-treated bed nets is promoted through a
National Malaria Control Programmes and artemether-
lumefantrine (Coartem™) is currently the first-line treat-
ment in Tanzania.
Study subjects
Eligibility criteria included any child born to a mother
who was HBsAg negative, aged between six and 10 weeks
at the time of first vaccination, who did not present with
any serious acute or chronic illness as determined by
clinical or physical examination, medical history records
or laboratory screening tests of haematology, and renal
and hepatic function.
Randomization and vaccination
Eligible subjects were randomized in a 1:1 ratio to re-
ceive three doses at 8, 12 and 16 weeks of age of either
RTS,S/AS02D (25 μg of lyophilized RTS,S reconstituted
with 500 μL of AS02D Adjuvant System) or three doses
of hepatitis B vaccine (Engerix-B™; GlaxoSmithKline).
All subjects received DTPw/Hib (TETRActHib™; Aventis
Pasteur) at 8, 12 and 16 weeks of age.
Surveillance of serious adverse events
A morbidity surveillance system in place at Bagamoyo
District Hospital (BDH) provided a comprehensive re-
cording of all inpatient and outpatient attendances, in-
vestigational results, diagnosis and management. All
parent(s)/guardian(s) of study children were educated on
the appropriate action they should take if their child be-
came unwell at any time during the study period; they
were asked not to medicate their child at home, but to
seek medical care at BDH. Sick children were provided
transport to go to BDH.
Study medical personnel
Were available 24 hours per day at BDH to receive and
identify study participants when they presented, and to
ensure complete investigation and documentation of the
attendance. At all other dispensaries in the study area,
study medical personnel were available 24 hours a day to
attend to patients and facilitate the transport of study
participants to BDH.
Evaluation of study subjects was according to IHI
Standard Operating Procedures for the examination, in-
vestigation and documentation of each presentation. Allinformation was recorded on an IHI clinic morbidity
surveillance questionnaire. The questionnaires were sub-
sequently reviewed by the Principal Investigator or dele-
gate and any SAE identified as appropriate.
Verbal autopsies were to be conducted on all children
who died outside a health facility to ascribe the cause of
death using a questionnaire adapted from the INDEPTH
standard questionnaire [14].
Immunogenicity assessment
During the follow-up phase of the study, antibody titres
for anti-CS and anti-HBs were assessed 12 months
(Month 14) and 18 months (Month 20) after the third
dose of vaccine. Antibody levels against CS were mea-
sured by standard ELISA methodology using plate-
adsorbed R32LR antigen [NVDP(NANP)15]2LR [7] and
expressed in ELISA Units/millilitre (EU/mL). Anti-HBs
was measured using a GSK developed ELISA immuno-
assay, in mIU/mL. Both assays were performed at the
laboratory of the Centre for Vaccinology (CEVAC),
Ghent, Belgium.
Monitoring for clinical malaria episodes
Passive case monitoring (PCD) for malaria episodes was
conducted at the health facilities within the study area
throughout the study period. In addition, there was
monitoring for the active detection of infection (ADI)
every two weeks up to the detection of a first infection
or up to study month 9. In summary, two weeks before
administration of the third vaccine dose, asymptomatic
parasitaemia was cleared with artemether–lumefantrine
comprising six doses during a three-day period. Absence
of parasitaemia after treatment was confirmed by blood
analysis obtained two weeks later. Any subject who con-
tinued to have parasitaemia was retreated and the event
excluded from the analysis. For ADI, blood samples were
taken for examination of malaria parasitaemia at each
visit. For PCD, any study subject presenting with fever
(axillary temperature ≥37.5°C) within the preceding
24 hours underwent a blood draw for the determination
of malaria parasites. Severe malaria was defined pro-
spectively according to an agreed case definition and
confirmed by medical review (Table 1).
Statistical analysis
An analysis plan was prospectively agreed upon by the
IDMC, sponsor and investigators. Statistical analyses were
conducted using SAS version 8 (SAS, Cary, NC, USA).
The primary study endpoint was of safety (occurrence of
SAEs up to Month 20) with secondary endpoints of
immunogenicity (anti-CS and anti-HBs antibody titres to
Month 20). Additional endpoints for efficacy were also
explored. All subjects who had received at least one dose
of study vaccine were included in the safety analysis. The
Table 1 Severe malaria definitions for reporting of SAEs
Severe malaria
anaemia
Asexual P. falciparum parasitemia > 0 definitive
reading
Haematocrit < 15%1
No other more probable cause of illness
Cerebral malaria Asexual P. falciparum parasitemia > 0 definitive
reading
Coma score ≤ 22
No other identifiable cause of loss of consciousness
Severe malaria
(other)
Asexual P. falciparum parasitemia > 0 definitive
reading
No other more probable cause of illness
Does not meet criteria for severe malaria anaemia
or cerebral malaria
One of the following:
Multiple seizures3
Prostration4
Hypoglycaemia5
Acidosis
Circulatory collapse
1. The lowest value recorded by either centrifuge or Coulter counter at any
point during the admission was used to determine a case.
2. Coma score assessed after correction of hypoglycaemia and 60 minutes
after control of fits. If fitting could not be controlled within 30 minutes child
was included.
3. Two or more generalised convulsions within a 24-hour period prior to
admission.
4. Inability to sit unaided.
5. < 2.2 mmol/dL or < 40 mg/dL.
Table 2 Case definitions for clinical malaria
Primary Case Definition • The presence of P. falciparum asexual
parasitaemia above 500 per μL) on
Giemsa stained thick blood films AND
• the presence of fever (axillary temperature
≥ 37.5°C)
Secondary Case
Definition
• The presence of P. falciparum asexual
parasitaemia above 0 per μL) on Giemsa
stained thick blood films AND
• the presence of fever (axillary temperature
≥ 37.5°C) or history of fever in the previous
24 hours
Abdulla et al. Malaria Journal 2013, 12:11 Page 4 of 11
http://www.malariajournal.com/content/12/1/11proportion of subjects with a SAE, classified by the Med-
ical dictionary for regulatory activities (MedDRA) pre-
ferred term level [15], was tabulated with exact 95% CI.
Episodes of severe malaria were tabulated with exact 95%
Confidence Intervals (CI).
The primary analysis for immunogenicity was per-
formed on the According to Protocol (ATP) cohort,
which included all evaluable subjects (i.e. those meeting
all eligibility criteria, complying with the procedures
defined in the protocol, with no elimination criteria dur-
ing the study) and for whom data concerning immuno-
genicity endpoints were available. The percentage of
subjects with seropositive levels of anti-CS antibodies
(cut-off ≥ 0.5 EU/mL) and seroprotective levels of anti-
HBs antibodies (cut-off ≥ 10 mIU/mL) with 95% CI were
assessed. Antibody titres were summarized by geometric
mean titres (GMT) with 95% CI for both antigens.
The primary exploratory analysis for efficacy was per-
formed on the ATP cohort, which included all enrolled
subjects for whom data concerning efficacy endpoint
measures were available, who received all 3 doses of
study vaccine according to the randomization list,
received clearance drug and were parasite negative at
the start of the ADI period. The study evaluated efficacy
against clinical malaria, according to primary and sec-
ondary case definitions (see Table 2). Time at risk started14 days post dose 3 and was corrected for absences from
the study area and anti-malarial drug use. Vaccine effi-
cacy (VE) against first or only episodes of clinical mal-
aria was assessed using Cox regression models, defined
as 1-R where R is the hazard ratio of the RTS,S/AS02D
group against control (with 95% CI). Schoenfeld p-
values and models with time varying covariates were
evaluated to check proportionality of hazards. VE against
multiple episodes was calculated using Poisson regres-
sion with random effects defined as 1- incident rate
ratio. For the ATP analyses, VE estimates were adjusted
for village of residence and distance to BDH.
Results
Subject cohort
A total of 340 infants were randomly assigned to a study
group and received at least one vaccination (Total Vacci-
nated Cohort: 170 RTS,S/AS02D, 170 hepatitis B vac-
cine). Figure 1 summarizes subject participation during
the course of the study. The month 20 visit was com-
pleted by 144 subjects in the RTS,S/AS02D group and
142 subjects in the hepatitis B vaccine group. From
month 0 to 20, 54 subjects withdrew from the study, 26
from the RTS,S/AS02D group and 28 from the hepatitis
B group. The main reason for withdrawal in both groups
was migration out of the study area.
The basic parameters of those withdrawing were not
different compared to the remaining study population.
The demographic profile of subjects in the RTS,S/AS02D
and hepatitis B vaccine groups was balanced in terms of
age and gender. At the time of first vaccine administra-
tion the mean age of subjects was 7.8 (SD 0.77) weeks
and 7.9 (SD 0.83) weeks in the RTS,S/AS02D and hepa-
titis B vaccine groups, respectively. A similar proportion
of subjects were males in both the RTS,S/AS02D and
hepatitis B vaccine groups (47% and 50%, respectively).
Safety outcomes
From the time of first vaccination until Month 20, 57
(33.5%) recipients of RTS,S/AS02D and 62 (36.5%) reci-
pients of hepatitis B vaccine, in co-administration with
DTPw/Hib, reported at least one SAE (Table 3). No SAE
340 infants randomised 
170 received dose 1 of RTS,S/AS02D 170 received dose 1 of Engerix-B
4 did not receive doses 2&3 
2 withdrew consent  
1 migrated 
2 migrated 
2 did not receive doses 2&3 
1 withdrew consent  
17 did not have access to EPI 
vaccines 
11 did not meet eligibility 
criteria 
5 were too late for enrolment 
3 could not have blood drawn 
2 withdrew consent 
7 migrated 
3 withdrew consent  
+6 followed-up but 
incomplete vaccination 
161 received dose 3 of Engerix-B
2 withdrew consent 
2 did not receive dose 3 
159 received dose 3 of RTS,S/AS02D
3 did not receive dose 3 
1 withdrew consent  
14 migrated 
2 withdrew consent  
1 died 
+5 followed-up but 
incomplete vaccination 
378 infants screened  
155 completed Month 14 visit 149 completed Month 14 visit 
144 completed Month 20 visit 142 completed Month 20 visit
5 migrated 
4 were lost to follow up 
1 withdrew consent  
1 died 
4 migrated 
3 were lost to follow up
163 received dose 2 of RTS,S/AS02D 165 received dose 2 of Engerix-B
Figure 1 CONSORT diagram for study participants. a Subjects were temporarily out of study area but returned for the Month 14 visit. b Other:
investigator decided not to continue vaccination as EPI vaccination documentation was not available, this subject returned for the Month 14 visit.
c One subject died after consent withdrawal; death was not considered related to vaccination.
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cine. There were no concerning imbalances in the cause
of SAEs.
Two SAEs were fatal, one occurring during the double-
blind phase (severe pneumonia/symptomatic seizure) in a
subject from the hepatitis B vaccine group and one during
the single-blind phase of the study (cerebral malaria) in a
subject from the RTS,S/AS02D group. On analysis of pre-
defined cases of severe malaria, five subjects in the RTS,S/AS02D group and four subjects in the hepatitis B vaccine
group were reported as having severe malaria. Apart from
the fatal SAEs, no subject was withdrawn from the study
due to an adverse event.
Immunogenicity outcomes
Anti-CS response
Pre-vaccination, a similar proportion of subjects was
seropositive for anti-CS antibodies in the RTS,S/AS02D
Table 3 SAEs occurring in more than one subject classified by MedDRA preferred term (Total Vaccinated Cohort
[Months 0–20])
Hepatitis B vaccine N = 170 RTS,S/AS02D N = 170
Preferred Term n % 95% CI n % 95% CI
At least one SAE 62 36.5 29.2 44.2 57 33.5 26.5 41.2
Pneumonia 36 21.2 15.3 28.1 25 14.7 9.7 20.9
P. falciparum infection 25 14.7 9.7 20.9 19 11.2 6.9 16.9
Anaemia 16 9.4 5.5 14.8 16 9.4 5.5 14.8
Gastroenteritis 12 7.1 3.7 12.0 16 9.4 5.5 14.8
Febrile convulsion 2 1.2 0.1 4.2 5 2.9 1.0 6.7
Urinary tract infection 3 1.8 0.4 5.1 4 2.4 0.6 5.9
Lymphadenitis 0 0.0 0.0 2.1 3 1.8 0.4 5.1
Abscess 2 1.2 0.1 4.2 2 1.2 0.1 4.2
Bronchiolitis 1 0.6 0.0 3.2 2 1.2 0.1 4.2
Sepsis 2 1.2 0.1 4.2 2 1.2 0.1 4.2
Upper respiratory tract infection 3 1.8 0.4 5.1 2 1.2 0.1 4.2
Convulsion 2 1.2 0.1 4.2 2 1.2 0.1 4.2
Acarodermatitis 2 1.2 0.1 4.2 0 0.0 0.0 2.1
Bronchial hyperreactivity 3 1.8 0.4 5.1 0 0.0 0.0 2.1
At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term).
N = number of subjects with at least one administered dose.
n/% = number/percentage of subjects reporting at least once the symptom.
95% CI = exact 95% confidence interval.
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Hib, groups (23.4% and 25.7%, respectively) (Table 4).
The pre-vaccination anti-CS antibody GMTs were below
the assay cut-off (<0.5 EU/mL) in both groups.
At month 14 and month 20, 75.4% and 71.8% of sub-
jects in the RTS,S/AS02D group were seropositive for
anti-CS antibodies, compared to 1.4% and 3.8% of sub-
jects in the hepatitis B vaccine group. At month 14, anti-
CS antibody GMTs in the RTS,S/AS02D were low (3.0
EU/mL) which decreased further at month 20 (1.9 EU/
mL), but were still higher than the hepatitis B control
group (<0.5 EU/mL).
Anti-HBs response
Subjects enrolled in this study were born to HBsAg-
negative mothers and no neonatal Hepatitis B immun-
ization programme was in place. Thus, the subjects had
received no previous Hepatitis B vaccine. Prior to vaccin-
ation, the proportion of subjects with seroprotective levels
of maternal anti-HBs antibodies derived from passive
transfer during pregnancy was similar in the RTS,S/AS02D
and hepatitis B vaccine, co-administered with DTPw/Hib,
groups (38.3% and 34.4%, respectively) (Table 5). On aver-
age, pre-vaccination anti-HBs antibody GMTs were low
(<15 mIU/mL).
Seroprotective levels of anti-HBs antibodies at month
20 were achieved in 100% of recipients of RTS,S/AS02D
co-administered with DTPw/Hib and 97.7% of recipientsof hepatitis B vaccine co-administered with DTPw/Hib.
The anti-HBs antibody GMT at Month 20 was greater in
recipients of RTS,S/AS02D (1521 mIU/mL) than in reci-
pients of hepatitis B vaccine (184 mIU/mL).
Efficacy outcomes
Over 12-month and 18-month periods following Dose 3
of study vaccine, VE of RTS,S/AS02D against the primary
case definition for multiple episodes of disease was 50.7%
(p = 0.072) and 26.7% (p = 0.307), respectively, and for first
or only episode of clinical malaria 53.6% (p = 0.026) and
34.9% (p = 0.101), respectively (Table 6). Figure 2 shows
Kaplan–Meier curves of the cumulative incidence of first
or only malaria episodes in the two study groups (Primary
Case Definition). In the intention to treat (ITT) popula-
tion vaccine efficacy against all episodes of malaria over
the entire follow up starting at dose 1 was 14.4% (95%
CI: -41.9 to 48.4, p = 0.545).
Over the same time periods, respectively, VE of RTS,S/
AS02D against the Secondary Case Definition for mul-
tiple episodes of disease was 53.5% (95% CI: 3.3, 77.6;
p = 0.040) and 26.2% (95% CI: -19.0, 54.2; p = 0.212)
and for first or only episode of clinical malaria was 55.7%
(95% CI: 15.4, 76.8; p = 0.014) and 32.0% (95% CI: -6.4,
56.5; p = 0.091). A test based on the Schoenfeld residuals
(p = 0.1919) suggested no violation of the proportional
hazards assumption over the follow up period, consistent
with a constant effect over the course of the study.
Table 4 Seropositivity rates and GMTs for anti-CS antibodies from Months 0 to 20 (ATP Cohort for Immunogenicity)
Group Timing N Seropositive GMT (EU/mL)
n % 95% CI value 95% CI
RTS,S/AS02D SCREENING 141 33 23.4 16.7 31.3 0.3 0.3 0.4
Post Dose 2 (Month 2) 151 149 98.7 95.3 99.8 28.9 22.4 37.3
Post Dose 3 (Month 3) 143 141 98.6 95.0 99.8 69.5 53.9 89.6
Post Dose 3 (Month 9) 143 127 88.8 82.5 93.5 6.2 4.6 8.3
Post Dose 3 (Month 14) 142 107 75.4 67.4 82.2 3.0 2.2 4.0
Post Dose 3 (Month 20) 131 94 71.8 63.2 79.3 1.9 1.4 2.6
Hepatitis B SCREENING 152 39 25.7 18.9 33.4 0.4 0.3 0.4
vaccine Post Dose 2 (Month 2) 156 10 6.4 3.1 11.5 0.3 0.3 0.3
Post Dose 3 (Month 3) 144 2 1.4 0.2 4.9 0.3 0.2 0.3
Post Dose 3 (Month 9) 147 0 0.0 0.0 2.5 0.3 0.3 0.3
Post Dose 3 (Month 14) 139 2 1.4 0.2 5.1 0.3 0.2 0.3
Post Dose 3 (Month 20) 132 5 3.8 1.2 8.6 0.3 0.3 0.3
Seropositive ≥ 0.5 EU/mL.
N = number of subjects with available results.
n/% = number/percentage of subjects with titre within the specified range.
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This paper further contributes key information on the
safety, immunogenicity and efficacy profile over a
20 month follow up period of the candidate malaria
RTS,S adjuvanted vaccine when co-administered to
infants alongside routine immunizations included in the
Expanded Programme of Immunization.
This study shows that, over 12 and 18 months of
follow up post vaccination: vaccine efficacy against mul-
tiple episodes of malaria disease was 50.7% and 26.7%,
respectively, in the ATP population. Vaccine efficacy
against multiple episodes of malaria disease in the ITT
population, starting at first dose of vaccine, was lower
(14%). Including ITT analysis provides fair comparisons
among the vaccinated population, but perfect adherence
to the protocol, especially for phase II studies, is crucial.
Results from ATP analyses aim to predict the true bio-
logical efficacy of the vaccine.Table 5 Seroprotective rates and GMTs for anti-HBs antibodie
Group Timing N Seroprotect
n %
RTS,S/AS02D SCREENING 115 44 3
Post Dose 2 (Month 2) 148 140 9
Post Dose 3 (Month 3) 140 140 1
Post Dose 3 (Month 20) 131 131 1
Hepatitis B SCREENING 131 45 3
vaccine Post Dose 2 (Month 2) 147 82 5
Post Dose 3 (Month 3) 141 133 9
Post Dose 3 (Month 20) 132 129 9
Seroprotected ≥ 10 mIU/mL.
N = number of subjects with available results.
n/% = number/percentage of subjects with titre within the specified range.Initial results demonstrated that RTS,S/AS02D has an
acceptable safety profile, that it can be given in co-
administration with EPI vaccines and provides protection
against first P. falciparum infection of approximately 65%
(p = 0.01) over 6 months of follow up [12].
As an exploratory endpoint in this follow up study, vac-
cine efficacy against multiple episodes of clinical disease
was 51%, though not achieving statistical significance
(p = 0.072), and 54% against first or only episode of clinical
disease (p = 0.026), over 12 months post-vaccination.
These results are consistent with those of a trial evaluat-
ing safety, immunogenicity and efficacy of RTS,S/AS01
in co-administration with EPI vaccines in infants [13].
Similar levels of protection have been observed in children
5–17 months old upon first RTS,S/AS01 vaccination in a
Phase II trial conducted in Tanzania and Kenya [16].
However, the large multi-country, multi-site RTS,S/
AS01 Phase III trial showed that in young infants thes from Months 0 to 20 (ATP Cohort for Immunogenicity)
ed GMT (mIU/mL)
95% CI Value 95% CI
8.3 29.4 47.8 14.5 10.9 19.2
4.6 89.6 97.6 110.9 89.1 138.1
00 97.4 100 667.3 532.9 835.7
00 97.2 100 1520.6 1206.8 1915.8
4.4 26.3 43.1 13.3 10.0 17.6
5.8 47.4 64.0 17.1 13.6 21.4
4.3 89.1 97.5 113.8 91.3 141.8
7.7 93.5 99.5 184.3 144.4 235.4
Table 6 Vaccine efficacy against P. falciparum disease (ATP Cohort for Efficacy)
RTS,S/AS02D Hepatitis B Vaccine Point estimate of VE adjusted for covariates
Subjects
(N)
No. of
events
PYAR Subjects
(N)
No. of
events
PYAR (%) 95% CI P value
Primary Case Definition: multiple episodes
Months 2.5 – 14
146 18 124.48 151 30 127.91 50.7 −6.5 77.1 0.072
Months 2.5 – 20
146 42 193.41 151 51 198.29 26.7 −33.1 59.6 0.307
Primary Case Definition: first or only
Months 2.5 – 14
146 13 121.04 151 24 121.34 53.6 8.6 76.4 0.026
Months 2.5 – 20
146 26 181.92 151 34 178.56 34.9 −8.8 61.1 0.101
PYAR: Episodes/Person Years at Risk; VE: Vaccine Efficacy (1-HR); CI: Confidence Interval; p value from Cox PH model; Poisson regression for multiple episodes.
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http://www.malariajournal.com/content/12/1/11vaccine provided modest protection against malaria
when co-administered with EPI vaccines [17]. The fact
that most of the participants in the Phase III study come
from high transmission areas indicates that RTS,S pro-
tection may be influenced by other factors including
level of transmission.
While CIs are wide, and models, including time-varying
covariates and Schoenfeld residuals (p = 0.192), do not
support waning in vaccine efficacy, a longer follow-up of
infants post-vaccination showed lower levels of protection
in this trial (27% over 18 months), which was not signifi-
cant at the 5% level (p = 0.307). This is in contrast with a
study with the RTS,S/AS01 formulation in infants, which
showed protection of 59% over 19 months of follow up
(p < 0.001) [18].
The reduction in the level of protection observed after
18 months, when compared to the level observed atNumber at risk
RTSS 146 141 138 133
Eng 151 145 140 135
Figure 2 Kaplan-Meier survival curves showing the cumulative incide
for Efficacy [Months 2.5 - 20]). Eng = Engerix-B Hepatitis B vaccine.12 months, was also reported in a study with 45 months
of follow up [19]. While it is not impossible that the
close follow up during the ADI period may have
impacted VE estimates in this trial, a possible explan-
ation could be due to a combination of (i) true decay in
vaccine-induced protection over the period of follow up,
(ii) the decline in the number of susceptible subjects due
to rapid acquisition of immunity, and/or (iii) variability
in malaria transmission and exposure. Similar observa-
tions were made in recent long-term follow-up studies
of RTS,S/AS02 [6,7,9-12,20,21].
The assessment of anti-CS antibody titres shows that
at 18 months post vaccination 71.8% of RTS,S/AS02
recipients remain seropositive. While remaining higher
than those seen in the control group, antibody levels are
much lower than early after vaccination. Although no pro-
tective threshold has been established, anti-CS antibodyp=0.2375 (log-rank test)
131 127 124 117 109
128 123 115 108 105
nce of P. falciparum disease, Primary Case Definition (ATP Cohort
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http://www.malariajournal.com/content/12/1/11levels have been shown to be associated with protection
[18,22,23]. The relatively low immune responses of RTS,S/
AS02 to anti-CS observed in this trial, compared to the
AS01E formulation, may have also contributed to the ap-
parent drop in long-term protection.
As seen in other studies of RTS,S/AS02 and RTS,S/
AS01 [3-13,22,23], post vaccination anti-HBs seroprotec-
tion rates and GMTs are high. In this study, at month 20
they remained greater than in recipients of hepatitis B
vaccine. This supports the fact that the RTS,S candidate
vaccine also confers protection against Hepatitis B virus
(HBV).
The observation of an acceptable safety profile of RTS,
S/ASO2D over 20 months of follow up is consistent with
long term safety follow up of RTS,S/AS01 in infants
[13]. No safety concerns appeared upon SAE review over
the duration of follow up. Few children died and severe
malaria rates were lower than expected in this setting,
which may be due to close follow up of this cohort. Clin-
ically diagnosed pneumonia, reported as SAEs and clas-
sified by MedDRA preferred terms [15], tended to be
more frequently reported among hospitalized partici-
pants in the hepatitis B vaccine group at 9 months post
vaccination [12], and this effect was less marked in the
current data set to 20 months. A tendency for pneumo-
nia rates to be lower may be due to a variety of reasons,
including chance findings, lack of accurate diagnosis for
pneumonia and/or the possibility that the malaria candi-
date vaccine reduced the indirect consequences of mal-
aria. A more rigorous assessment of the co-morbidities
is ongoing in the Phase III trial [17,22].
The acceptable vaccine safety profile and the efficacy
data obtained in this trial in the context of co-
administration of EPI vaccines adds to the growing body
of evidence that, if approved, the RTS,S candidate vac-
cine could contribute to the reduction of the malaria
disease burden in infants and children and become an
additional component of integrated malaria control
strategies.
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